A relapse in pedophilic sex offending and subsequent suicide attempt during luteinizing hormone-releasing hormone treatment
Open accessAbstract
Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.Sir: In 1998, Rösler and Witztum1 published the first systematic study of antihormonal treatment of paraphilias with luteinizing hormone-releasing hormone (LHRH) agonists. Since the publication of their promising results, there has been an increasing interest in this new form of treatment.2 Our recently published review3 in the Journal revealed that 118 patients did not relapse if they remained on LHRH treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There has been at least one case report of treatment failure and attempted suicide associated with GnRH use (Briken 2004).
“and there has been at least one case report of treatment failure and attempted suicide associated with GnRH use (Briken 2004).”
From Pharmacological interventions for those who have sexually offended or are at risk of offending (2015) · cites this paper as Briken 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Poulin, J., Daoust, A.-M., Forest, G., Stip, E., & Godbout, R. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00346-8 · Cited by 160 · see citing works
Sleep loss and postpartum psychosis
Sharma, V., & Mazmanian, D. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00015.x · Cited by 150 · see citing works
Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia
Chemerinski, E., Ho, B.-C., Flaum, M., Arndt, S., Fleming, F., & Andreasen, N. C. (2002) · Comprehensive Psychiatry · doi:10.1053/comp.2002.34627 · Cited by 101 · see citing works
Flagged first, then by citations
Research works printed but not linked: 43
- Rösler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 1998;338:416-422
- Fagan PJ, Wise TN, Schmidt CW Jr, et al. Pedophilia. JAMA 2002;288:2458-2465
- Briken P, Hill A, Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J Clin Psychiatry 2003;64:890-897
- Rösler A, Witztum E. Pharmacotherapy of the paraphilias in the next millennium. Behav Sci Law 2000;18:43-56
- Briken P, Nika E, Berner W. Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. J Sex Marital Ther 2001;27: 45-55 REFERENCES
- Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004;56:187-190
- Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74:371-375
- Danoff SK, Grasso ME, Terry PB, et al. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001;120:313-316
- Flowers CM, Racoosin JA, Lu SL, et al. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731
- Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003;46:349-362 REFERENCES
- Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74:371-375
- Rains CP, Bryson HM, Fitton A. Cabergoline: a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995;49: 255-279
- Bhatt MH, Keenan SP, Fleetham JA, et al. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30: 613-616
- Flowers CM, Racoosin JA, Lu SL, et al. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731
- Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992;5:263-265
- Fritsch PO, Ruiz-Maldonado R. Stevens-Johnson syndrome: toxic epidermal necrolysis. In: Freedberg IM, Eisen AZ, Wolff K, et al. Fitzpatrick's Dermatology in General Medicine, vol 1. 5th ed. New York, NY: McGraw Hill; 1999:644-653
- Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-360
- Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hyper- sensitivity syndrome. Dermatol Online J 2002;8:5. Available at: http://dermatology.cdlib.org/DOJvol8num1/reviews/drugrxn/ ghislain.html. Accessed Aug 22, 2004
- Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-729
- Labreze CL, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000;83:347-353
- Warnock CA, Azadian AG. Cross-sensitivity between paroxetine and sertraline. Ann Pharmacother 2002;36:631-633
- Jan V, Toledano C, Machet L, et al. Stevens-Johnson syndrome after sertraline [letter]. Acta Derm Venereol 2000;42:287
- Bodokh I, Lacour JP, Rosenthal E, et al. Lyell syndrome or toxic epidermal necrolysis and Stevens-Johnson syndrome after fluoxetine [in French] [letter]. Thérapie 1992;47:411
- Vincent A, Douville M, Baruch P. Serum sickness induced by fluoxe- tine [letter]. Am J Psychiatry 1991;148:1602-1603
- Wolkenstein P, Arevuz J, Diehl JL. Toxic epidermal necrolysis after fluvoxamine [letter]. Lancet 1993;342:304-305
- Tripathi A, Greenburger PA. Bupropion hydrochloride induced serum sickness-like reaction. Ann Allergy Asthma Immunol 1999;83: 165-166
- Bagshaw SM, Cload B, Gilmour J, et al. Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Ann Allergy Asthma Immunol 2003;90:572-575
- Warnock JK, Knesevich JW. Adverse cutaneous reactions to antide- pressants. Am J Psychiatry 1988;145:425-430
- Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther 2003;25:2138-2154
- Beauclaire L, Radoi-Andraous D, Chouinard G. Selective serotonin- noradrenaline reuptake inhibitors. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:2427-2432
- Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59:502-508
- Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-61S
- Sidwell RU, Swift S, Yan C-L, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. Int J Clin Pract 2003;57:643-645 REFERENCES
- West JL, Jenzen HH, Lester BK. The psychosis of sleep deprivation. Ann N Y Acad Sci 1962;96:66-70
- Olney RK. Mescaline. Tex Med 1972;7:80-82
- Harley-Mason J, Laird AH, Smythies JR. The metabolism of mescalin in the human: delayed clinical reactions to mescalin. Confin Neurol 1958;18:152-155
- Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000;31:302-312
- Gove WR. Sleep deprivation: a cause of psychotic disorganization. AJS 1970;75:782-799
- McGuire BE, Basten CJ, Ryan CJ, et al. Intensive care unit syndrome. Arch Intern Med 2000;160:906-909
- Wright JBD. Mania following sleep deprivation. Br J Psychiatry 1993;163:679-680
- Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry 1980;137:801-805
- King D. Pathological and therapeutic consequences of sleep loss: a review. Dis Nerv Syst 1977;11:873-879
- Snyder F. Dynamic aspects of sleep disturbance in relation to mental illness. Biol Psychiatry 1969;1:119-130
Cited by
Sorted by citations
Pharmacological interventions for those who have sexually offended or are at risk of offending
Khan, O., Ferriter, M., Huband, N., Powney, M. J., Dennis, J. A., & Duggan, C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007989.pub2 · Cited by 144 · see citing works
Psychological interventions for adults who have sexually offended or are at risk of offending
Dennis, J. A., Khan, O., Ferriter, M., Huband, N., Powney, M. J., & Duggan, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007507.pub2 · Cited by 112 · see citing works
Drug treatment of paraphilic and nonparaphilic sexual disorders
Guay, D. R. P. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.01.009 · Cited by 129 · see citing works
Thibaut, F., Cosyns, P., Fedoroff, J. P., Briken, P., Goethals, K., Bradford, J. M. W., & The WFSBP Task Force on Paraphilias (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1744723 · Cited by 109 · see citing works
“However, in one case report (Briken et al. 2004), the patient relapsed while being treated with leuprolide acetate treatment and committed a sex offence.”
BackgroundSelf-citationCurrent concepts in the pharmacotherapy of paraphilias
Garcia, F. D., & Thibaut, F. (2011) · Drugs · doi:10.2165/11585490-000000000-00000 · Cited by 85 · see citing works
Turner, D., & Briken, P. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2017.11.013 · Cited by 81 · see citing works
Self-citationThe Oregon depo-Provera Program: A Five-Year Follow-Up
Maletzky, B., Tolan, A., & Mcfarland, B. (2006) · Sexual abuse. A Journal of Research and Treatment · doi:10.1177/107906320601800308 · Cited by 58 · see citing works
Briken, P., Welzel, K., Habermann, N., Hill, A., & Berner, W. (2009) · Psychiatrische Praxis · doi:10.1055/s-0028-1090221 · Cited by 25 · see citing works
Self-citationPharmacological treatment of sex offenders
Thibaut, F. (2011) · European psychiatry · doi:10.1016/j.eurpsy.2016.01.895 · Cited by 19
The Oregon depo-Provera Prograxm: A Five-Year Follow-Up
Maletzky, B., Tolan, A., & Mcfarland, B. (2006) · Sexual Abuse · doi:10.1007/s11194-006-9021-4 · Cited by 13 · see citing works
Pharmacotherapy of Sexual Offenders and Men who are at Risk of Sexual Offending
Briken, P., Hill, A., & Berner, W. (2011) · doi:10.1002/9781119990420.ch21 · Cited by 9 · see citing works
Self-citationChemical Castration as an Evolving Concept: Is It a Possible Solution for Sexual Offences?
Çöpür, M., & Çöpür, S. (2020) · Journal of Forensic Psychiatry and Psychology · doi:10.1080/14789949.2020.1849359 · Cited by 5 · see citing works
“(Briken et al., 2004) Mechanism of action of cyproterone acetate (CPA) consists of antagonistic effects at androgen receptors, weak inhibition of 5α-reductase enzyme and potent progestogenic activity which in turn leads to negative feedback in gonadotropic hormone secretion (Schroder, 1993).”
BackgroundTherapieangebote für Männer mit sexuellen Präferenzstörungen und Sexualdelinquenz
Berner, W., & Briken, P. (2010) · Forensische Psychiatrie Psychologie Kriminologie · doi:10.1007/s11757-010-0072-5 · Cited by 6 · see citing works
Self-citationTreatment of Paraphilic Disorders
Baez-Sierra, D., Balgobin, C., & Wise, T. (2016) · doi:10.1007/978-3-319-42650-1_4 · Cited by 4
Traitement pharmacologique des délinquants sexuels
Thibaut, F. (2011) · Sexologies · doi:10.1016/j.sexol.2011.02.004 · Cited by 1 · see citing works
Erectile Functioning as a Risk Factor for Committing a Sexual Offense?
Briken, P., & Turner, D. (2022) · Journal of Sexual Medicine · doi:10.1016/j.jsxm.2022.03.218
Self-citation
- Authors
- Briken, P., Hill, A., & Berner, W.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-10-15
- Volume
- 65
- Issue
- 10
- Pages
- 1429
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2079870043
- Cited by
- 18
- References
- 0
- Citations by year
- 2022: 1 · 2020: 2 · 2019: 2 · 2017: 1 · 2016: 1 · 2015: 1 · 2013: 1
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychopathy, Forensic Psychiatry, Sexual Offending
- Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- pedophilic disorder, sexual offending, relapse, suicide attempts, GnRH agonist
- MeSH terms
- Adolescent, Adult, Fantasy, Humans, Gonadotropin-Releasing Hormone, Male, Pedophilia, Risk Factors, Sex Offenses, Suicide, Attempted, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
